← Back to Search

Penicillin Antibiotic

Amoxicillin for Pneumonia

Phase 2 & 3
Recruiting
Led By Jocelyn Gravel, MD
Research Sponsored by St. Justine's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Presence of respiratory symptoms (cough and/or dyspnea)
Presence of signs of pneumonia (tachypnea, abnormal breath sounds, crackles)
Must not have
Need hospitalization for any other reasons (ie. persistent vomiting, severe life-threatening infection such as septicemia or meningitis requiring intravenous antimicrobial agents)
Any danger signs associated with pneumonia (severe indrawing, shock or severe dehydration, empyema, important pleural effusion, pulmonary abscess or pneumatocoele)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Summary

This trial will compare a twice-daily to a thrice-daily antibiotic regimen for the treatment of non-severe community acquired pneumonia in children.

Who is the study for?
This trial is for children aged 3 months to 18 years with non-severe community acquired pneumonia, showing symptoms like cough, fever, and abnormal breath sounds. They must have signs of pneumonia on a chest X-ray. Kids with severe allergic reactions to amoxicillin, chronic illnesses, or recent hospital stays are excluded.Check my eligibility
What is being tested?
The study tests if taking the antibiotic Amoxicillin twice daily is just as effective as three times daily for treating non-severe pneumonia in kids who visit the emergency department.See study design
What are the potential side effects?
Amoxicillin may cause side effects such as allergic reactions (rash), gastrointestinal issues (nausea, vomiting), and rarely more serious conditions like Stevens-Johnson syndrome.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have symptoms like coughing or difficulty breathing.
Select...
I am showing signs of pneumonia, like rapid breathing and unusual lung sounds.
Select...
I am between 3 months and 18 years old with a diagnosis of non-severe pneumonia.
Select...
I have a fever.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not need hospitalization for conditions like severe infections.
Select...
I have severe symptoms related to pneumonia.
Select...
I do not have any unstable chronic illnesses like cystic fibrosis or active TB.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical failure within 10 days of enrolment
Secondary outcome measures
Adverse events
Clinical recurrence
Emergency department revisit within 72 hours
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Twice a day regimenExperimental Treatment1 Intervention
Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
Group II: Thrice a day regimenActive Control1 Intervention
Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amoxicillin
2017
Completed Phase 4
~7780

Find a Location

Who is running the clinical trial?

St. Justine's HospitalLead Sponsor
196 Previous Clinical Trials
77,972 Total Patients Enrolled
Jocelyn Gravel, MDPrincipal InvestigatorSainte-Justine Hospital
5 Previous Clinical Trials
1,587 Total Patients Enrolled

Media Library

Amoxicillin (Penicillin Antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT03031210 — Phase 2 & 3
Community-acquired Pneumonia Research Study Groups: Thrice a day regimen, Twice a day regimen
Community-acquired Pneumonia Clinical Trial 2023: Amoxicillin Highlights & Side Effects. Trial Name: NCT03031210 — Phase 2 & 3
Amoxicillin (Penicillin Antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03031210 — Phase 2 & 3
~169 spots leftby Jul 2025